Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.

van Langelaar J, Rijvers L, Janssen M, Wierenga-Wolf AF, Melief MJ, Siepman TA, de Vries HE, Unger PA, van Ham SM, Hintzen RQ, van Luijn MM.

Ann Neurol. 2019 Aug;86(2):264-278. doi: 10.1002/ana.25508. Epub 2019 Jun 19.

2.

The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis.

Rijvers L, Melief MJ, van der Vuurst de Vries RM, Stéphant M, van Langelaar J, Wierenga-Wolf AF, Hogervorst JM, Geurts-Moespot AJ, Sweep FCGJ, Hintzen RQ, van Luijn MM.

Eur J Immunol. 2018 Nov;48(11):1861-1871. doi: 10.1002/eji.201847623. Epub 2018 Sep 25.

3.

Chemical and genetic control of IFNγ-induced MHCII expression.

Wijdeven RH, van Luijn MM, Wierenga-Wolf AF, Akkermans JJ, van den Elsen PJ, Hintzen RQ, Neefjes J.

EMBO Rep. 2018 Sep;19(9). pii: e45553. doi: 10.15252/embr.201745553. Epub 2018 Jul 18.

4.

High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.

van der Vuurst de Vries RM, Wong YYM, Mescheriakova JY, van Pelt ED, Runia TF, Jafari N, Siepman TA, Melief MJ, Wierenga-Wolf AF, van Luijn MM, Samijn JP, Neuteboom RF, Hintzen RQ.

Mult Scler. 2019 Jun;25(7):958-967. doi: 10.1177/1352458518775303. Epub 2018 May 18.

5.

T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.

van Langelaar J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, Spilt IM, Siepman TA, Dankers W, Verjans GMGM, de Vries HE, Lubberts E, Hintzen RQ, van Luijn MM.

Brain. 2018 May 1;141(5):1334-1349. doi: 10.1093/brain/awy069.

PMID:
29659729
6.

Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients.

van Nierop GP, van Luijn MM, Michels SS, Melief MJ, Janssen M, Langerak AW, Ouwendijk WJD, Hintzen RQ, Verjans GMGM.

Acta Neuropathol. 2017 Sep;134(3):383-401. doi: 10.1007/s00401-017-1744-4. Epub 2017 Jun 17.

7.

Elevated Expression of the Cerebrospinal Fluid Disease Markers Chromogranin A and Clusterin in Astrocytes of Multiple Sclerosis White Matter Lesions.

van Luijn MM, van Meurs M, Stoop MP, Verbraak E, Wierenga-Wolf AF, Melief MJ, Kreft KL, Verdijk RM, 't Hart BA, Luider TM, Laman JD, Hintzen RQ.

J Neuropathol Exp Neurol. 2016 Jan;75(1):86-98.

PMID:
26683597
8.

Genetic Variants in MicroRNAs and Their Binding Sites Are Associated with the Risk of Parkinson Disease.

Ghanbari M, Darweesh SK, de Looper HW, van Luijn MM, Hofman A, Ikram MA, Franco OH, Erkeland SJ, Dehghan A.

Hum Mutat. 2016 Mar;37(3):292-300. doi: 10.1002/humu.22943. Epub 2015 Dec 31.

PMID:
26670097
9.

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

van Luijn MM, van den Ancker W, van Ham SM, van de Loosdrecht AA.

Oncoimmunology. 2015 Jan 7;3(12):e941737. eCollection 2014 Dec.

10.

Multiple sclerosis-associated CLEC16A controls HLA class II expression via late endosome biogenesis.

van Luijn MM, Kreft KL, Jongsma ML, Mes SW, Wierenga-Wolf AF, van Meurs M, Melief MJ, der Kant Rv, Janssen L, Janssen H, Tan R, Priatel JJ, Neefjes J, Laman JD, Hintzen RQ.

Brain. 2015 Jun;138(Pt 6):1531-47. doi: 10.1093/brain/awv080. Epub 2015 Mar 29.

11.

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2014 Jun;38(6):691-3. doi: 10.1016/j.leukres.2014.03.014. Epub 2014 Mar 25.

PMID:
24731748
12.

Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.

van Luijn MM, Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA, Marieke van Ham S.

Oncoimmunology. 2012 Mar 1;1(2):211-213.

13.

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

van Luijn MM, van de Loosdrecht AA, Lampen MH, van Veelen PA, Zevenbergen A, Kester MG, de Ru AH, Ossenkoppele GJ, van Hall T, van Ham SM.

PLoS One. 2012;7(4):e34649. doi: 10.1371/journal.pone.0034649. Epub 2012 Apr 26.

14.

Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.

van Luijn MM, Westers TM, Chamuleau ME, van Ham SM, Ossenkoppele GJ, van de Loosdrecht AA.

Am J Pathol. 2011 Nov;179(5):2157-61. doi: 10.1016/j.ajpath.2011.07.027. Epub 2011 Sep 9.

15.

Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.

van Luijn MM, van den Ancker W, Chamuleau ME, Zevenbergen A, Westers TM, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA.

Cancer Res. 2011 Apr 1;71(7):2507-17. doi: 10.1158/0008-5472.CAN-10-3689. Epub 2011 Feb 10.

16.

Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.

van den Ancker W, van Luijn MM, Ruben JM, Westers TM, Bontkes HJ, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2011 Jan;60(1):37-47. doi: 10.1007/s00262-010-0917-y. Epub 2010 Sep 22.

17.

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM.

Cancer Immunol Immunother. 2010 Dec;59(12):1825-38. doi: 10.1007/s00262-010-0908-z. Epub 2010 Sep 5.

18.

Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.

van Luijn MM, van den Ancker W, Chamuleau ME, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA.

Immunotherapy. 2010 Jan;2(1):85-97. doi: 10.2217/imt.09.84. Review.

PMID:
20635891
19.

Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Westers TM, Bontkes HJ, Ruben JM, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA.

Immunotherapy. 2010 Jan;2(1):69-83. doi: 10.2217/imt.09.85. Review.

PMID:
20635890
20.

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA.

Haematologica. 2010 Mar;95(3):485-93. doi: 10.3324/haematol.2009.010595. Epub 2009 Nov 10.

Supplemental Content

Loading ...
Support Center